TTF-1/Thyroid Transcription Factor 1/NKX2-1 CRISPR/Cas9 KO Plasmid (m): sc-423405

Overview

Nkx2-1 encodes TTF-1 (thyroid transcription factor 1), a homeodomain-containing transcription factor that orchestrates lineage specification and differentiation programs in the thyroid, lung epithelium, and regions of the ventral forebrain. NKX2-1 regulates gene networks involved in epithelial identity, morphogenesis, and secretory function, including pathways controlling surfactant production and thyroid hormone biosynthesis. Through enhancer binding and cooperative interactions with other developmental regulators, it helps maintain tissue-specific transcriptional states and chromatin accessibility. Dysregulated NKX2-1 activity or expression is linked to developmental abnormalities and is frequently studied in the context of thyroid and pulmonary disease biology as well as lineage-associated tumorigenesis and cell fate transitions.

TTF-1/Thyroid Transcription Factor 1/NKX2-1 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Nkx2-1 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Nkx2-1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Nkx2-1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish TTF-1/Thyroid Transcription Factor 1/NKX2-1 protein expression.

This CRISPR knockout system enables efficient generation of Nkx2-1-deficient cell models for investigation of TTF-1/Thyroid Transcription Factor 1/NKX2-1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

Key Features

• sgRNAs targeting Nkx2-1 exon(s) critical for TTF-1/Thyroid Transcription Factor 1/NKX2-1 function
• Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
• GFP reporter for identification of transfected cells
• Pool of plasmids targeting multiple Nkx2-1 genomic sites to improve knockout efficiency
• Compatible with delivery by transfection

Design Variants

CRISPRs +/- HDRs

• gRNAs encoded by TTF-1/Thyroid Transcription Factor 1/NKX2-1 CRISPR/Cas9 KO Plasmid (m) and TTF-1/Thyroid Transcription Factor 1/NKX2-1 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Nkx2-1 locus. One or both targeting designs may be available. See Related Products for availability.
• HDR donor constructs encoded by TTF-1/Thyroid Transcription Factor 1/NKX2-1 HDR Plasmid (m) and TTF-1/Thyroid Transcription Factor 1/NKX2-1 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Nkx2-1 homology arms to support homology-directed repair at defined Nkx2-1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.